Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: An updated meta-analysis of randomized placebo-controlled trials

Journal of Psychiatric Research

Volumn 47, Issue 12, 2013, Pages 2018-2020

  Matsuda, Yuki ^a   Kishi, Taro ^a   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amantadine; Efficacy; Memantine; Meta analysis; NMDA receptor antagonists; Tolerability

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; CLOZAPINE; MEMANTINE; OLANZAPINE; PLACEBO; RISPERIDONE;

BIPOLAR DISORDER; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INSOMNIA; LETTER; META ANALYSIS (TOPIC); MINI MENTAL STATE EXAMINATION; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT REDUCTION;

AMANTADINE; EFFICACY; MEMANTINE; META-ANALYSIS; NMDA RECEPTOR ANTAGONISTS; TOLERABILITY;

ANTIPSYCHOTIC AGENTS; HUMANS; MEMANTINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84886102138     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.09.002     Document Type: Letter

References (14)

1. Angus S., Sugars J., Boltezar R., Koskewich S., Schneider N.M. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1997, 17:88-91.
2. Correll C.U., Manu P., Olshanskiy V., Napolitano B., Kane J.M., Malhotra A.K. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 302:1765-1773.
3. de Lucena D., Fernandes B.S., Berk M., Dodd S., Medeiros D.W., Pedrini M., et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009, 70:1416-1423.
4. Deberdt W., Winokur A., Cavazzoni P.A., Trzaskoma Q.N., Carlson C.D., Bymaster F.P., et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 2005, 15:13-21.
5. Graham K.A., Gu H., Lieberman J.A., Harp J.B., Perkins D.O. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 2005, 162:1744-1746.
6. Kishi T., Iwata N. NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomized, placebo-controlled trials. J Psychiatr Res 2013 Sep, 47(9):1143-1149. Epub 2013 May 18. 10.1016/j.jpsychires.2013.04.013.
7. Lee J.G., Lee S.W., Lee B.J., Park S.W., Kim G.M., Kim Y.H. Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investig 2012, 9:166-173.
8. LeLorier J., Gregoire G., Benhaddad A., Lapierre J., Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997, 337:536-542.
9. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013 Sep 14, 382(9896):951-962. Epub 2013 Jun 27. PMID: 23810019 [PubMed - in process]. 10.1016/S0140-6736(13)60733-3.
10. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
11. Lieberman J.A., Papadakis K., Csernansky J., Litman R., Volavka J., Jia X.D., et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacol 2009, 34:1322-1329. Group, M.-M.-S.
12. Pappa S., Tsouli S., Apostolou G., Mavreas V., Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 2010, 33:271-275.
13. Rezaei F., Mohammad-Karimi M., Seddighi S., Modabbernia A., Ashrafi M., Salehi B., et al. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2013, 33:336-342.
14. Silver H., Goodman C., Isakov V., Knoll G., Modai I. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int Clin Psychopharmacol 2005, 20:319-326.